| Project ID: | MCC-001 |
| Sample ID: | MCC-001-01-1A |
| Submitted by: | NCBI (GEO) |
| Country: | USA |
| BioProject | PRJNA483959 |
| Sample name | NA |
| SRA accession: | SRP155988 |
| SRS accession: | SRS3693909 |
| SRX accession: | SRX4579480 |
| SRR accession: | SRR7722938 |
| GEO accession: | GSE117988 |
| Cancer type: | Merkel Cell Carcinoma |
| Cancer type abbreviation: | MCC |
| Primary site: | Skin |
| Tissue: | Skin |
| Tumor grade: | NA |
| Tumor status: | Metastatic |
| Donor age: | 59 |
| Donor gender: | Male |
| Treatment: | Cellular immunotherapy targeting MCPyV (autologous endogenous T cell therapy) followed by checkpoint inhibitors (anti-PD1 and anti-CTLA4) |
| Other metadata: | The patient had a 22 month clinical response followed by late/acquired resistance. |
| Project title: | scRNAseq reveals mechanisms of Merkel cell carcinoma acquired immunotherapy resistance [1] |
| Project abstract: | Serial blood draws from a single patient and serial tumor biopsies from the same patient with metastatic Merkel cell polyomavirus Merkel cell carcinoma, who was treated with cellular immunotherapy targeting MCPyV (autologous endogenous T cell therapy) followed by checkpoint inhibitors (anti-PD1 and anti-CTLA4). The patient had a 22 month clinical response followed by late/acquired resistance. We performed scRNAseq using the 10X Genomics 3'' Chromium expression assay to determine potential mechanisms contributing to immunotherapy response and late resistance Overall design: Serial blood draws from four time points, serial tumor biopsies from two time points - single cell digests were viably preserved, comparisons were performed on a within tissue basis, discovery patient for associated manuscript. |
| Construction protocol: | PBMC were isolated with standard FICOLL, tumor tissues were digested in RPMI with DNAse, Collagenase, and hyaluronidase, strained and frozen. All samples were thawed on same day and immediately processed 10X Genomics Gene Expression 3' Chromium V 2.0 per manufacturer's instructions. |
| Protocol: | 10X Genomics |
| Instrument: | Illumina HiSeq 2500 |
| Strategy: | RNA-Seq |
| Layout: | PAIRED |
| Publications: | K.G. Paulson et al., Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature Communications, 2018, 9(1): 3868 |
